文献速递肝病消化道肿瘤与早癌

肝硬化患者肝细胞癌生长模式异质性的多中心队列研究

Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis.
PubMed 文献 · Hepatology · 2020-10-25

该回顾性多中心队列纳入欧美6个医疗系统2008–2017年诊断的肝硬化合并肝细胞癌患者,要求治疗前至少两次间隔≥30天的增强影像。主要队列242例中位肿瘤倍增时间229天,38%呈惰性生长、25.2%呈快速生长;惰性生长与较大肿瘤直径和AFP<20 ng/mL相关,非病毒性肝硬化更常见。

要点

  • 肝硬化肝细胞癌生长异质性明显,约四分之一呈快速生长。
  • 惰性生长与较大肿瘤直径及AFP<20 ng/mL独立相关。
  • 非病毒性肝硬化患者惰性生长比例高于病毒性肝硬化。

核心结论

  • 在大型西方肝细胞癌队列中观察到异质性肿瘤生长模式,约四分之一呈快速生长,超过三分之一呈惰性生长。
  • 更好理解不同肿瘤生长模式可能有助于精准预后判断和治疗决策。

研究设计与样本

  • 回顾性多中心队列研究,纳入2008–2017年美国与欧洲6个医疗系统中诊断肝细胞癌的肝硬化患者。
  • 主要队列242例来自4个中心,独立验证队列176例来自2个中心,均要求治疗前至少两次间隔≥30天的增强影像。
  • 由放射科医生独立三维测量肿瘤以计算肿瘤倍增时间和特定生长率。

主要发现

  • 主要队列中位肿瘤倍增时间为229天(IQR 89–627),中位特定生长率为每日0.3%(IQR 0.1%–0.8%)。
  • 主要队列中38%为惰性生长、36.8%为中间生长、25.2%为快速生长。
  • 惰性生长与较大肿瘤直径相关(OR 1.15,95%CI 1.03–1.30)。
  • 惰性生长与AFP<20 ng/mL相关(OR 1.90,95%CI 1.12–3.21)。
  • 非病毒性肝硬化惰性生长比例为50.9%,病毒性为32.1%;T1期肝细胞癌中惰性生长OR为3.41(95%CI 1.08–10.80)。

关键数值与推荐

  • 惰性生长定义为肿瘤倍增时间>365天,快速生长定义为肿瘤倍增时间<90天。
  • 主要队列中位肿瘤倍增时间229天(IQR 89–627),中位特定生长率每日0.3%(IQR 0.1%–0.8%)。
  • 惰性生长与较大肿瘤直径的OR为1.15(95%CI 1.03–1.30),与AFP<20 ng/mL的OR为1.90(95%CI 1.12–3.21)。
  • T1期肝细胞癌中非病毒性肝硬化与惰性生长的OR为3.41(95%CI 1.08–10.80)。
  • 独立验证队列中位肿瘤倍增时间169天(IQR 74–408),特定生长率每日0.4%。

临床怎么用

  • 临床可参考肿瘤倍增时间识别惰性生长肝细胞癌,避免过度治疗。
  • 对快速生长肝细胞癌应加强监测并尽早干预。
  • 较大肿瘤直径和AFP<20 ng/mL提示惰性生长可能,可辅助个体化决策。
  • 非病毒性肝硬化尤其T1期患者惰性生长可能性更高,需结合生长模式制定随访策略。

局限性

  • 回顾性研究设计可能存在选择偏倚。
  • 主要队列仅来自4个中心,独立队列来自2个中心,外推性需进一步验证。
  • 肿瘤测量依赖影像学三维评估,可能存在测量变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: There are limited data on hepatocellular carcinoma (HCC) growth patterns, particularly in Western cohorts, despite implications for surveillance, prognosis, and treatment. Our study's aim was to quantify tumor doubling time (TDT) and identify correlates associated with indolent and rapid growth. APPROACH AND RESULTS: We performed a retrospective multicenter cohort study of patients with cirrhosis diagnosed with HCC from 2008 to 2017 at six US and European health systems with two or more contrast-enhanced imaging studies performed ≥ 30 days apart prior to HCC treatment. Radiologists independently measured tumors in three dimensions to calculate TDT and specific growth rate (SGR). We used multivariable ordinal logistic regression to identify factors associated with indolent (TDT > 365 days) and rapid (TDT < 90 days) tumor growth. In the primary cohort (n = 242 patients from four centers), median TDT was 229 days (interquartile range [IQR], 89-627) and median SGR was 0.3% per day (IQR, 0.1%-0.8%). Over one-third (38%) of HCCs had indolent growth, 36.8% intermediate growth, and 25.2% rapid growth. In multivariable analysis, indolent growth was associated with larger tumor diameter (odds ratio [OR], 1.15, 95% confidence interval [CI], 1.03-1.30) and alpha-fetoprotein < 20 ng/mL (OR, 1.90; 95% CI, 1.12-3.21). Indolent growth was more common in nonviral than viral cirrhosis (50.9% versus 32.1%), particularly in patients with T1 HCC (OR, 3.41; 95% CI, 1.08-10.80). Median TDT (169 days; IQR 74-408 days) and SGR (0.4% per day) were similar in an independent cohort (n = 176 patients from two centers). CONCLUSIONS: In a large Western cohort of patients with HCC, we found heterogeneous tumor growth patterns, with one-fourth exhibiting rapid growth and over one-third having indolent growth. Better understanding different tumor growth patterns may facilitate a precision approach to prognostication and treatment.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Rich NE, John BV, Parikh ND, et al. Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis. Hepatology. 2020. PMID: 32017165. doi:10.1002/hep.31159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。